Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Pier Luigi Zinzani; Robert Chen; Philippe Armand; Nathalie A. Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P. Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A. Shipp; Jianxin Lin; Akash Nahar; Arun Balakumaran; Craig H. Moskowitz

doi:10.1080/10428194.2019.1702178

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Pier Luigi Zinzani, Robert Chen, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz^*

^*Corresponding author for this work

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

Original language	English
Journal	Leukemia and Lymphoma
Early online date	6 Jan 2020
DOIs	https://doi.org/10.1080/10428194.2019.1702178
Publication status	E-pub ahead of print - 6 Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2019.1702178

Cite this

Zinzani, P. L., Chen, R., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Lin, J., Nahar, A., Balakumaran, A., & Moskowitz, C. H. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia and Lymphoma. Advance online publication. https://doi.org/10.1080/10428194.2019.1702178

@article{c45ba9888557475e8f1df169ecc4bf78,

title = "Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis",

author = "Zinzani, {Pier Luigi} and Robert Chen and Philippe Armand and Johnson, {Nathalie A.} and Pauline Brice and John Radford and Vincent Ribrag and Daniel Molin and Vassilakopoulos, {Theodoros P.} and Akihiro Tomita and {von Tresckow}, Bastian and Shipp, {Margaret A.} and Jianxin Lin and Akash Nahar and Arun Balakumaran and Moskowitz, {Craig H.}",

year = "2020",

month = jan,

day = "6",

doi = "10.1080/10428194.2019.1702178",

language = "English",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

Zinzani, PL, Chen, R, Armand, P, Johnson, NA, Brice, P, Radford, J, Ribrag, V, Molin, D, Vassilakopoulos, TP, Tomita, A, von Tresckow, B, Shipp, MA, Lin, J, Nahar, A, Balakumaran, A & Moskowitz, CH 2020, 'Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2019.1702178

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. / Zinzani, Pier Luigi; Chen, Robert; Armand, Philippe et al.
In: Leukemia and Lymphoma, 06.01.2020.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy

T2 - KEYNOTE-087 subgroup analysis

AU - Zinzani, Pier Luigi

AU - Chen, Robert

AU - Armand, Philippe

AU - Johnson, Nathalie A.

AU - Brice, Pauline

AU - Radford, John

AU - Ribrag, Vincent

AU - Molin, Daniel

AU - Vassilakopoulos, Theodoros P.

AU - Tomita, Akihiro

AU - von Tresckow, Bastian

AU - Shipp, Margaret A.

AU - Lin, Jianxin

AU - Nahar, Akash

AU - Balakumaran, Arun

AU - Moskowitz, Craig H.

PY - 2020/1/6

Y1 - 2020/1/6

UR - http://www.scopus.com/inward/record.url?scp=85078638645&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1702178

DO - 10.1080/10428194.2019.1702178

M3 - Letter

C2 - 31905294

AN - SCOPUS:85078638645

SN - 1042-8194

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Zinzani PL, Chen R, Armand P, Johnson NA, Brice P, Radford J et al. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia and Lymphoma. 2020 Jan 6. Epub 2020 Jan 6. doi: 10.1080/10428194.2019.1702178

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

UN SDGs

Access to Document

Other files and links

Cite this